Dr. Umar

This study used 16S rRNA sequencing to compare gut microbiomes of Alzheimer’s patients and controls, revealing reduced Bacteroidetes and increased Actinobacteria and Ruminococcaceae, suggesting microbe-driven influences on AD pathology.

This study identifies reduced diversity and distinct microbial shifts in Alzheimer’s disease, linking specific bacterial genera with amyloid and tau biomarkers and supporting a role for gut–brain interactions in AD.

This study links increased Escherichia/Shigella and reduced Eubacterium rectale to heightened inflammation and amyloidosis, defining a gut microbiome amyloidosis association that may contribute to Alzheimer-related pathology.

This study analyzed the salivary microbiome in Alzheimer’s disease, revealing reduced diversity and distinct microbial shifts, including Moraxella enrichment and APOE4-related differences, suggesting oral dysbiosis may contribute to neurodegeneration.

The study shows that gut microbiota in mild cognitive impairment closely matches Alzheimer’s disease, revealing early dysbiosis involving reduced diversity, elevated gram-negative bacteria, and diminished Bacteroidetes, supporting microbiome-based early biomarker development.

This study links the Alzheimer’s disease microbiome to reduced butyrate-producing bacteria and impaired intestinal P-gp regulation, revealing a proinflammatory gut signature that may contribute to neurodegenerative processes.

This study identified major microbial and metabolic disruptions in Chinese Alzheimer’s patients, highlighting reduced butyrate producers, increased lactate producers, and strong correlations with cognition and inflammation.

This study identifies stage-specific salivary microbiome changes across dementia progression, showing declines in periodontal bacteria and rises in opportunistic species. Integrating microbial signatures with olfactory testing enhances early diagnostic potential.

Longitudinal analysis in APP/PS1 mice shows gut microbiome alterations emerging months before amyloid plaques or microglial activation, highlighting inflammation-linked taxa as early biomarkers and mechanistic contributors to Alzheimer’s disease pathology.

This study links altered gut microbiota and fecal metabolites to Alzheimer’s disease, identifying a combined microbial–metabolite signature that strongly discriminates AD from controls and reveals metabolic pathways tied to neuroinflammation.

This study used long-read 16S sequencing to compare oral microbiota Alzheimer’s disease profiles in elderly adults, revealing reduced diversity and distinct increases in Firmicutes and Streptococcaceae alongside loss of Fusobacterium, suggesting microbiome biomarkers for early AD detection.

This study links APOE-ε4 gut microbiota dysbiosis to Alzheimer disease, showing increased Proteobacteria and reduced SCFA-producing taxa in genetically susceptible individuals, highlighting microbial–genetic interactions in AD pathogenesis.

Newly diagnosed Chinese patients with MCI and AD exhibit progressive gut microbiome dysbiosis, marked by increased Prevotella and reduced Bacteroides, Lachnospira, and Ruminiclostridium 9, with microbial patterns correlating with cognitive decline.

Study links parasympathetic inhibition to gut microbiota changes that distinguish healthy aging, mild cognitive impairment, and Alzheimer’s disease, identifying microbial signatures that track cognitive decline.

Aβ1–42 injection induced cognitive decline, intestinal inflammation, and distinct gut microbiota dysbiosis via suppression of cholinergic anti-inflammatory pathways, linking central amyloid pathology to peripheral microbial and immune disruption.

This study examined gut microbiota differences in Kazakh Alzheimer’s patients, revealing reduced SCFA-producing genera and increased pro-inflammatory taxa, with strong links to metabolic biomarkers and disease severity.

This study shows that gut microbiota stratification in Alzheimer’s disease is driven mainly by Prevotella- and Bacteroides-dominant communities, with inflammatory enterotypes enriched in AD, offering potential for biomarker development and precision nutrition strategies.

The study shows that MCI mirrors AD-associated gut dysbiosis, highlighting early microbial shifts involving Escherichia and reduced Bacteroides. These findings support microbiota-based biomarkers for pre-dementia detection.

This study used full-length 16S sequencing to characterize oral microbiota changes in Alzheimer’s disease, revealing reduced diversity, elevated Firmicutes, and distinct microbial biomarkers linked to inflammation and cognitive decline.

This study shows that gut microbiota drive Alzheimer’s pathology through PUFA-linked neuroinflammation, with Bacteroides species and arachidonic-acid metabolites activating microglia and worsening amyloid and tau lesions.

Integrated microbiome–metabolome profiling revealed that specific subgingival species and GCF metabolites strongly track with cognitive decline, offering potential diagnostic markers for Alzheimer’s disease within the oral–brain axis framework.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age, characterized by irregular menstrual cycles, hyperandrogenism, and insulin resistance. It is often associated with metabolic dysfunctions and inflammation, leading to fertility issues and increased risk of type 2 diabetes and cardiovascular disease.

This study shows that the saliva microbiome in PCOS is altered across all time points and loses normal diurnal rhythmicity, with elevated Fusobacteria and reduced Actinobacteria contributing to inflammatory and metabolic risk.

Letrozole-induced hyperandrogenemia reshapes the gut microbiome, reducing diversity and altering key Bacteroidetes and Firmicutes taxa linked to metabolic dysfunction.